370 related articles for article (PubMed ID: 34341335)
1. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment.
Terpos E; Gavriatopoulou M; Ntanasis-Stathopoulos I; Briasoulis A; Gumeni S; Malandrakis P; Fotiou D; Papanagnou ED; Migkou M; Theodorakakou F; Roussou M; Eleutherakis-Papaiakovou E; Kanellias N; Trougakos IP; Kastritis E; Dimopoulos MA
Blood Cancer J; 2021 Aug; 11(8):138. PubMed ID: 34341335
[TBL] [Abstract][Full Text] [Related]
2. Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study.
Gavriatopoulou M; Terpos E; Ntanasis-Stathopoulos I; Briasoulis A; Gumeni S; Malandrakis P; Fotiou D; Migkou M; Theodorakakou F; Eleutherakis-Papaiakovou E; Kanellias N; Kastritis E; Trougakos IP; Dimopoulos MA
Blood Adv; 2021 Nov; 5(21):4398-4405. PubMed ID: 34529762
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
4. Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine.
Gavriatopoulou M; Terpos E; Malandrakis P; Ntanasis-Stathopoulos I; Briasoulis A; Gumeni S; Fotiou D; Papanagnou ED; Migkou M; Theodorakakou F; Eleutherakis-Papaiakovou E; Kanellias N; Trougakos IP; Kastritis E; Dimopoulos MA
Br J Haematol; 2022 Jan; 196(2):356-359. PubMed ID: 34528249
[TBL] [Abstract][Full Text] [Related]
5. Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors.
Terpos E; Zagouri F; Liontos M; Sklirou AD; Koutsoukos K; Markellos C; Briasoulis A; Papanagnou ED; Trougakos IP; Dimopoulos MA
J Hematol Oncol; 2021 May; 14(1):86. PubMed ID: 34059088
[TBL] [Abstract][Full Text] [Related]
6. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.
Terpos E; Trougakos IP; Gavriatopoulou M; Papassotiriou I; Sklirou AD; Ntanasis-Stathopoulos I; Papanagnou ED; Fotiou D; Kastritis E; Dimopoulos MA
Blood; 2021 Jul; 137(26):3674-3676. PubMed ID: 33861315
[No Abstract] [Full Text] [Related]
7. Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers.
Terpos E; Trougakos IP; Karalis V; Ntanasis-Stathopoulos I; Gumeni S; Apostolakou F; Sklirou AD; Gavriatopoulou M; Skourti S; Kastritis E; Korompoki E; Papassotiriou I; Dimopoulos MA
Cells; 2021 Jul; 10(8):. PubMed ID: 34440710
[TBL] [Abstract][Full Text] [Related]
8. Clinical and immunological outcomes of SARS-CoV-2-infected vaccine responders, vaccine non-responders, and unvaccinated patients evaluated for neutralizing monoclonal antibody treatment at a single German tertiary care center: a retrospective cohort study with prospective follow-up.
Triebelhorn J; Schneider J; Spinner CD; Iakoubov R; Voit F; Wagner L; Erber J; Rothe K; Berthele A; Pernpeintner V; Strauß EM; Renders L; Willmann A; Minic M; Vogel E; Christa C; Hoffmann D; Protzer U; Jeske SD
Infection; 2024 Jun; 52(3):1143-1151. PubMed ID: 38305828
[TBL] [Abstract][Full Text] [Related]
9. First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19.
Mazzoni A; Di Lauria N; Maggi L; Salvati L; Vanni A; Capone M; Lamacchia G; Mantengoli E; Spinicci M; Zammarchi L; Kiros ST; Rocca A; Lagi F; Colao MG; Parronchi P; Scaletti C; Turco L; Liotta F; Rossolini GM; Cosmi L; Bartoloni A; Annunziato F;
J Clin Invest; 2021 Jun; 131(12):. PubMed ID: 33939647
[TBL] [Abstract][Full Text] [Related]
10. 18-month longitudinal SARS COV-2 neutralizing antibody dynamics in haemodialysis patients receiving heterologous 3-dose vaccination (AZD-1222- AZD-1222- BNT162b2) in a lower middle income setting.
Karunathilake RP; Kumara RA; Karunathilaka A; Wazil AWM; Nanayakkara N; Bandara CK; Abeysekera RA; Noordeen F; Gawarammana IB; Ratnatunga CN
BMC Nephrol; 2024 May; 25(1):176. PubMed ID: 38778281
[TBL] [Abstract][Full Text] [Related]
11. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.
Pimpinelli F; Marchesi F; Piaggio G; Giannarelli D; Papa E; Falcucci P; Pontone M; Di Martino S; Laquintana V; La Malfa A; Di Domenico EG; Di Bella O; Falzone G; Ensoli F; Vujovic B; Morrone A; Ciliberto G; Mengarelli A
J Hematol Oncol; 2021 May; 14(1):81. PubMed ID: 34001183
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2.
Favresse J; Gillot C; Di Chiaro L; Eucher C; Elsen M; Van Eeckhoudt S; David C; Morimont L; Dogné JM; Douxfils J
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372570
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Antibody Response to the BNT162b2 mRNA Vaccine in Persons with Past Natural Infection.
Kang YM; Choe KW; Lee KD; Kim KN; Kim MJ; Lim J
J Korean Med Sci; 2021 Sep; 36(35):e250. PubMed ID: 34490757
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
15. Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies.
Malard F; Gaugler B; Gozlan J; Bouquet L; Fofana D; Siblany L; Eshagh D; Adotevi O; Laheurte C; Ricard L; Dulery R; Stocker N; van de Wyngaert Z; Genthon A; Banet A; Memoli M; Ikhlef S; Sestilli S; Vekhof A; Brissot E; Marjanovic Z; Chantran Y; Cuervo N; Ballot E; Morand-Joubert L; Mohty M
Blood Cancer J; 2021 Aug; 11(8):142. PubMed ID: 34376633
[TBL] [Abstract][Full Text] [Related]
16. Robust induction of neutralizing antibodies against the SARS-CoV-2 Delta variant after homologous Spikevax or heterologous Vaxzevria-Spikevax vaccination.
Hammerschmidt SI; Thurm C; Bošnjak B; Bernhardt G; Reinhold A; Willenzon S; Ritter C; Reinhold D; Schraven B; Förster R
Eur J Immunol; 2022 Feb; 52(2):356-359. PubMed ID: 34870322
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignancies.
Terpos E; Fotiou D; Karalis V; Ntanasis-Stathopoulos I; Sklirou AD; Gavriatopoulou M; Malandrakis P; Iconomidou VA; Kastritis E; Trougakos IP; Dimopoulos MA
Am J Hematol; 2022 Oct; 97(10):1300-1308. PubMed ID: 35871310
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang H; Wang W; Zhang W; Li N; Xie Z; Ding L; You W; Zhao Y; Yang X; Liu Y; Wang Q; Huang L; Yang Y; Xu G; Luo B; Wang W; Liu P; Guo W; Yang X
Lancet Infect Dis; 2021 Jan; 21(1):39-51. PubMed ID: 33069281
[TBL] [Abstract][Full Text] [Related]
19. Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.
Schramm R; Costard-Jäckle A; Rivinius R; Fischer B; Müller B; Boeken U; Haneya A; Provaznik Z; Knabbe C; Gummert J
Clin Res Cardiol; 2021 Aug; 110(8):1142-1149. PubMed ID: 34241676
[TBL] [Abstract][Full Text] [Related]
20. Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.
Zani A; Caccuri F; Messali S; Bonfanti C; Caruso A
Emerg Microbes Infect; 2021 Dec; 10(1):1241-1243. PubMed ID: 34092181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
